立体定向放射外科与全脑放疗在颅内转移瘤切除术后的比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项回顾性队列研究共646例患者,比较颅内转移瘤切除术后立体定向放射外科(SRS)与全脑放疗(WBRT)的疗效。结果显示SRS与WBRT在局部复发、远处复发和总生存方面可能相当,但SRS与更高的软脑膜病变风险相关,且一项研究报告SRS的放射性坏死风险更高。
要点
- SRS与WBRT的局部复发、远处复发风险无显著差异,总生存可能相当。
- SRS与更高的软脑膜病变风险相关(RR 2.99,95%CI 1.55-5.76)。
- SRS的白质脑病风险更低,但放射性坏死风险更高(基于单项研究)。
核心结论
- 基于回顾性队列研究,SRS可能提供与WBRT相当的总生存、局部控制和远处控制。
- SRS可能与更高的软脑膜病变风险相关。
研究设计与样本
- 系统综述与荟萃分析,检索Pubmed、Embase和Cochrane数据库至2016年6月。
- 纳入8项回顾性队列研究,共646例患者(SRS 238例,WBRT 408例)。
主要发现
- 局部复发风险比(固定效应模型)为0.59(95%CI 0.32-1.09,I2=3.35%,P异质性=0.36,3项研究)。
- 远处复发风险比为1.09(95%CI 0.74-1.60,I2=50.5%,P异质性=0.13,3项研究)。
- 软脑膜病变风险比为2.99(95%CI 1.55-5.76,I2=14.4%,P异质性=0.28,2项研究)。
- 中位总生存风险比在固定效应模型为0.47(95%CI 0.41-0.54,I2=79.1%,P异质性<0.01,4项研究),随机效应模型为0.63(95%CI 0.40-1.00)无显著性。
- SRS与更低的白质脑病风险相关(RR 0.15,95%CI 0.07-0.33,1项研究),但与更高的放射性坏死风险相关(RR 19.4,95%CI 1.21-310,1项研究)。
关键数值与推荐
- SRS与WBRT比较,局部复发、远处复发、软脑膜病变、总生存的风险比如上。
- 白质脑病和放射性坏死的风险比基于单项研究。
临床怎么用
- 对于颅内转移瘤切除术后患者,SRS可作为WBRT的替代选择,但需警惕软脑膜病变风险。
- SRS可能降低白质脑病风险,但需注意放射性坏死风险。
局限性
- 纳入研究均为回顾性队列研究,存在选择偏倚等混杂因素。
- 部分结局指标纳入研究数量少(如软脑膜病变仅2项研究,白质脑病和放射性坏死仅1项研究)。
- 总生存分析异质性高(I2=79.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with one to three brain metastases who undergo resection, options for post-operative treatments include whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) of the resection cavity. In this meta-analysis, we sought to compare the efficacy of each post-operative radiation modality with respect to tumor recurrence and survival. METHODS: Pubmed, Embase and Cochrane databases were searched through June 2016 for cohort studies reporting outcomes of SRS or WBRT after metastasis resection. Pooled effect estimates were calculated using fixed-effect and random-effect models for local recurrence, distant recurrence, and overall survival. RESULTS: Eight retrospective cohort studies with 646 patients (238 with SRS versus 408 with WBRT) were included in the analysis. Comparing SRS to WBRT, the overall crude risk ratio using the fixed-effect model was 0.59 for local recurrence (95%-CI: 0.32-1.09, I2: 3.35%, P-heterogeneity = 0.36, 3 studies), 1.09 for distant recurrence (95%-CI: 0.74-1.60, I2: 50.5%, P-heterogeneity = 0.13; 3 studies), and 2.99 for leptomeningeal disease (95% CI 1.55-5.76; I2: 14.4% p-heterogeneity: 0.28; 2 studies). For the same comparison, the risk ratio for median overall survival was 0.47 (95% CI: 0.41-0.54; I2: 79.1%, P-heterogeneity < 0.01; 4 studies) in a fixed-effect model, but was no longer significant (0.63; 95%-CI: 0.40-1.00) in a random-effect model. SRS was associated with a lower risk of leukoencephalopathy (RR: 0.15, 95% CI: 0.07-0.33, 1 study), yet with a higher risk of radiation-necrosis (RR: 19.4, 95% CI: 1.21-310, 1 study). CONCLUSION: Based on retrospective cohort studies, the results of this study suggest that SRS of the resection cavity may offer comparable survival and similar local and distant control as adjuvant WBRT, yet may be associated with a higher risk for developing leptomeningeal disease. Future research on SRS should focus on achieving a better understanding of the various factors that may favor SRS over WBRT.
引用
- Lamba N, Muskens IS, DiRisio AC, et al. Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol. 2017. PMID: 28646895. doi:10.1186/s13014-017-0840-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。